Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the advances Pfizer is making in helping prevent and treat certain infectious diseases, particularly respiratory illnesses. This will include research featured in the IDWeek press program assessing the potential public health impact of ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for maternal immunization to protect infants against RSV illness.
Bayer to partner with Twist Bioscience to accelerate drug discovery
- Details
- Category: Bayer
Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.
The company's "Library of Libraries", a collection of synthetic antibody libraries that harness innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
- Details
- Category: Novartis
At an Extraordinary General Meeting, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.
Shareholders also approved an ordinary capital decrease of the share capital of Novartis AG in the amount of the share capital of Sandoz.
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- Details
- Category: Bayer
Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, VVD-130037. Vividion is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG.
GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Details
- Category: GlaxoSmithKline
GSK and Save the Children have announced today that they are renewing their award-winning partnership for a further five years. GSK will invest £15 million in the partnership with Save the Children and they will work together to increase child vaccination rates, with a focus on reducing the number of 'zero dose' children in Ethiopia and Nigeria.
Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
- Details
- Category: Bayer
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.
More Pharma News ...
- Novartis completes acquisition of Chinook Therapeutics
- U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
- Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
- AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults
- Pfizer's ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
- Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
- Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries